A 54-year-old woman with a left breast mass was referred to our hospital. Mammography showed a mass, 2.1cm in size, with micro-lobulated boarders. Ultrasonography showed an oval mass with predominant low internal echoes and enhanced posterior echoes. Core needle biopsy of the tumor showed malignant cells and chondroid matrices. With MRI, the tumor was hypo-intense on T1-weighted images, mixed hyper- and hypo-intense on T2-weighted images, and completely rim enhanced until late phase on time-signal intensity curve. Despite the good indication for breast conserving therapy, patient's preference made her undergo total mastectomy, sentinel lymph node biopsy, and immediate breast reconstruction using an extended latissimus dorsi musculocutaneous flap. Postoperative pathologic study showed large acellular areas, atypical cells growing in cord-like and linear fashions with cartilage-like matrices, and no spindle cells / osteoclasts between the cancer cells and chondroid matrices, leading to the pathologic diagnosis of matrix-producing carcinoma. The patient received dose-dense chemotherapy as an adjuvant therapy and has been well without any recurrences for 14 months. Physicians should note that partial hypo-intensity on T2-weighted images and retained rim enhancement to the late phase should be important findings of breast matrix-producing carcinoma.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597748 | PMC |
http://dx.doi.org/10.1016/j.radcr.2023.09.084 | DOI Listing |
Int J Radiat Oncol Biol Phys
December 2024
Division of Radiation Oncology, National Cancer Centre Singapore, Singapore.
Purpose: Metaplastic breast cancer (MBC) is a rare and heterogeneous breast cancer subtype, and there are critical gaps in our understanding of its long-term outcomes. This retrospective cohort study aimed to address these gaps by scrutinizing the pathologic and clinical aspects of MBC to enhance clinical decision-making and refine patient care strategies.
Methods And Materials: This registry-based retrospective cohort study included women aged ≥21 years diagnosed with MBC or matrix-producing carcinoma.
Cureus
December 2023
Department of Pathology, UPMC (University of Pittsburgh Medical Center) Magee-Womens Hospital, Pittsburgh, USA.
Metaplastic breast carcinoma represents a diverse category of invasive breast cancers distinguished by the transformation of neoplastic epithelial cells into squamous cells or cells with mesenchymal appearance. Matrix-producing breast carcinoma is a variant of metaplastic breast carcinoma, an exceedingly uncommon malignancy accounting for less than 1% of all breast tumors. The precise origin of this tumor remains elusive; some molecular research points to a potential derivation from myoepithelial cells, while other studies emphasize the possibility of neoplastic transformation originating from multipotent stem cells.
View Article and Find Full Text PDFKey Clinical Message: A rare form of invasive breast carcinoma, NOS, also known as matrix-producing carcinoma made up of epithelial and mesenchymal components. Usually, they are triple negative and clinically aggressive and respond poorly to neoadjuvant systemic therapy.
Abstract: Metaplastic breast carcinomas (MBCs) are ductal carcinomas that undergo metaplasia to form nonglandular growth patterns.
Radiol Case Rep
January 2024
Department of Surgery, Kishiwada Tokushukai Hospital, Kishiwada-City, Japan.
A 54-year-old woman with a left breast mass was referred to our hospital. Mammography showed a mass, 2.1cm in size, with micro-lobulated boarders.
View Article and Find Full Text PDFJ Clin Pathol
October 2024
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Aims: Secretory carcinoma of breast (SCB) typically harbours gene fusion. Pan-Trk immunohistochemistry analysis (IHC) has been shown to be sensitive for SCB diagnosis. However, weak focal pan-Trk nuclear staining was previously found in 10% of non-secretory breast carcinomas.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!